Literature DB >> 30338612

Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.

Marta Betti1, Anna Aspesi1, Daniela Ferrante2, Marika Sculco1, Luisella Righi3, Dario Mirabelli4, Francesca Napoli3, Milena Rondón-Lagos5, Elisabetta Casalone6,7, Francesca Vignolo Lutati8, Paola Ogliara8, Paolo Bironzo9, C Laura Gironi1, Paola Savoia1, Antonella Maffè10, Silvana Ungari10, Federica Grosso11, Roberta Libener12, Renzo Boldorini13, Michele Valiante14, Barbara Pasini8, Giuseppe Matullo6,7,8, Giorgio Scagliotti9, Corrado Magnani2, Irma Dianzani1.   

Abstract

Pathogenic germline variants in the BAP1 tumor suppressor gene can cause a cancer syndrome called BAP1 tumor predisposition syndrome (BAP1-TPDS), which is characterized by predisposition to mesothelioma, melanoma, renal cell carcinoma, basal cell carcinoma, and other tumors. Other genes that may predispose to mesothelioma are CDKN2A and DNA repair genes. Asbestos exposure has often been reported in patients with malignant pleural mesothelioma (MPM) and germline variants in BAP1, but this exposure has never been quantified. We aimed to search for germline variants in BAP1 among 25 new Italian probands with suspected BAP1-TPDS, summarize the prevalence of these variants in 39 Italian patients with familial MPM and other tumors recruited over a 5-year period, and compare cumulative asbestos exposure in 14 patients with MPM and pathogenic germline variants in BAP1, CDKN2A, or DNA repair genes with that of 67 patients without germline variants in 94 cancer-predisposing genes. We report here a new pathogenic germline variant in BAP1: c.783 + 2 T > C. The prevalence of pathogenic germline variants in BAP1 was 7.7% among patients with familial MPM (3/39). Patients with pathogenic germline variants in BAP1, CDKN2A, or DNA repair genes showed lower cumulative asbestos exposure than patients without germline variants in 94 cancer-predisposing genes (P = .00002). This suggests an interaction between genetic risk factors and asbestos in the development of mesothelioma.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  BAP1; BAP1-TPDS; DNA repair genes; cumulative asbestos exposure; germline variants; mesothelioma

Mesh:

Substances:

Year:  2018        PMID: 30338612     DOI: 10.1002/gcc.22670

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Authors:  Raffit Hassan; Betsy Morrow; Anish Thomas; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Meghana Gadiraju; Vasiliki Panou; Shaojian Gao; Idrees Mian; Javed Khan; Mark Raffeld; Snehal Patel; Liqiang Xi; Jun S Wei; Mary Hesdorffer; Jingli Zhang; Kathleen Calzone; Arpita Desai; Emerson Padiernos; Christine Alewine; David S Schrump; Seth M Steinberg; Hedy L Kindler; Mary-Claire King; Jane E Churpek
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 2.  Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Authors:  Michele Carbone; Harvey I Pass; Guntulu Ak; H Richard Alexander; Paul Baas; Francine Baumann; Andrew M Blakely; Raphael Bueno; Aleksandra Bzura; Giuseppe Cardillo; Jane E Churpek; Irma Dianzani; Assunta De Rienzo; Mitsuru Emi; Salih Emri; Emanuela Felley-Bosco; Dean A Fennell; Raja M Flores; Federica Grosso; Nicholas K Hayward; Mary Hesdorffer; Chuong D Hoang; Peter A Johansson; Hedy L Kindler; Muaiad Kittaneh; Thomas Krausz; Aaron Mansfield; Muzaffer Metintas; Michael Minaai; Luciano Mutti; Maartje Nielsen; Kenneth O'Byrne; Isabelle Opitz; Sandra Pastorino; Francesca Pentimalli; Marc de Perrot; Antonia Pritchard; Robert Taylor Ripley; Bruce Robinson; Valerie Rusch; Emanuela Taioli; Yasutaka Takinishi; Mika Tanji; Anne S Tsao; A Murat Tuncer; Sebastian Walpole; Andrea Wolf; Haining Yang; Yoshie Yoshikawa; Alicia Zolondick; David S Schrump; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2022-04-21       Impact factor: 20.121

Review 3.  Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.

Authors:  Luca Ferrari; Michele Carugno; Carolina Mensi; Angela Cecilia Pesatori
Journal:  Front Oncol       Date:  2020-04-03       Impact factor: 6.244

Review 4.  Metabolic rewiring and redox alterations in malignant pleural mesothelioma.

Authors:  Loredana Urso; Ilaria Cavallari; Evgeniya Sharova; Francesco Ciccarese; Giulia Pasello; Vincenzo Ciminale
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

5.  Case Report and Review of Literature: Familial Malignant Pleural Mesothelioma in a 39 Years Old Patient With an Inconclusive 18F-FDG PET/CT Result.

Authors:  Mayar Idkedek; Kareem S Tahayneh; Firas Abu-Akar; Izzeddin A Bakri
Journal:  Front Surg       Date:  2022-03-14

6.  UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Authors:  Emily S Reardon; Vivek Shukla; Sichuan Xi; Sudheer K Gara; Yi Liu; David Straughan; Mary Zhang; Julie A Hong; Eden C Payabyab; Anju Kumari; William G Richards; Assunta De Rienzo; Raffit Hassan; Markku Miettinen; Liqiang Xi; Mark Raffeld; Lisa T Uechi; Xinmin Li; Ruihong Wang; Haobin Chen; Chuong D Hoang; Raphael Bueno; David S Schrump
Journal:  J Thorac Oncol       Date:  2020-09-11       Impact factor: 15.609

Review 7.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

8.  Asbestos Air Pollution: Description of a Mesothelioma Cluster Due to Residential Exposure from an Asbestos Cement Factory.

Authors:  Luigi Vimercati; Domenica Cavone; Maria Celeste Delfino; Antonio Caputi; Luigi De Maria; Stefania Sponselli; Vincenzo Corrado; Giovanni Maria Ferri; Gabriella Serio
Journal:  Int J Environ Res Public Health       Date:  2020-04-12       Impact factor: 3.390

Review 9.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02

Review 10.  Mesothelioma developing in carriers of inherited genetic mutations.

Authors:  Yoshie Yoshikawa; Mitsuru Emi; Takashi Nakano; Giovanni Gaudino
Journal:  Transl Lung Cancer Res       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.